Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144

The Lancet Infectious Diseases

Volumn 12, Issue 7, 2012, Pages 531-537

  Robb, Merlin L ^a   Rerks Ngarm, Supachai ^b   Nitayaphan, Sorachai ^c   Pitisuttithum, Punnee ^d   Kaewkungwal, Jaranit ^d,e   Kunasol, Prayura ^b   Khamboonruang, Chirasak ^b   Thongcharoen, Prasert ^b   Morgan, Patricia ^c,f   Benenson, Michael ^c,f   Paris, Robert M ^g   Chiu, Joseph ^h   Adams, Elizabeth ^h   Francis, Donald ⁱ   Gurunathan, Sanjay ^j   Tartaglia, Jim ^j   Gilbert, Peter ^k   Stablein, Don ^l   Michael, Nelson L ^a   Kim, Jerome H ^a,m  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Biophics   (Thailand)

^f Henry Jackson Foundation   (United States)

^g WALTER REED ARMY MEDICAL CENTER   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ Global Solutions for Infectious Diseases   (United States)

^j SANOFI PASTEUR   (France)

^k Fred Hutchinson Cancer Research Center   (United States)

^l EMMES CORPORATION   (United States)

^m US Army Medical Materiel Development Activity   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AIDSVAX B/E VACCINE; ALVAC HIV VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; THAILAND; TIME SERIES ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ADULT; AIDS VACCINES; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; QUESTIONNAIRES; RISK-TAKING; STATISTICS, NONPARAMETRIC; SUBSTANCE ABUSE, INTRAVENOUS; THAILAND; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84862764447     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70088-9     Document Type: Article

References (27)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
2. Plotkin SA Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47:401-409.
3. Letvin NL, Rao SS, Montefiori DC, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011, 3:81ra36.
4. Reynolds MR, Weiler AM, Piaskowski SM, et al. Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J Virol 2010, 84:9190-9199.
5. Lee D, Graham BS, Chiu YL, et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 2004, 190:903-907.
6. Van Rompay KK, Abel K, Lawson JR, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005, 38:124-134.
7. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93.
8. Phoolcharoen W HIV/AIDS prevention in Thailand: success and challenges. Science 1998, 280:1873-1874.
9. UNGASS country progress report: Thailand. Reporting Period January 2006-December 2007 National AIDS Prevention and Alleviation Committee, (accessed Oct 19, 2009). http://data.unaids.org/pub/Report/2008/thailand_2008_country_progress_report_en.pdf.
10. Gilbert PB, Wei LJ, Kosorok MR, Clemens JD Simultaneous inferences on the contrast of two hazard functions with censored observations. Biometrics 2002, 58:773-780.
11. Fisher M, Benn P, Evans B, et al. UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. Int J STD AIDS 2006, 17:81-92.
12. Michael NL, Moore JP Viral phenotype and CCR5 genotype. Nat Med 1999, 5:1330.
13. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
14. Liu J, Keele BF, Li H, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010, 84:10406-10412.
15. Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010, 84:6241-6247.
16. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009, 206:1117-1134.
17. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009, 9:118-129.
18. Baggaley RF, White RG, Boily MC HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010, 39:1048-1063.
19. Thomas C Roadblocks in HIV research: five questions. Nat Med 2009, 15:855-859.
20. Burton DR, Desrosiers RC, Doms RW, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004, 303:316.
21. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008, 14:617-621.
22. Garber DA, Silvestri G, Feinberg MB Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis 2004, 4:397-413.
23. Korber BT, Letvin NL, Haynes BF T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 2009, 83:8300-8314.
24. Virgin HW, Walker BD Immunology and the elusive AIDS vaccine. Nature 2010, 464:224-231.
25. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
26. Esparza J, Chang ML, Widdus R, Madrid Y, Walker N, Ghys PD Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study). Vaccine 2003, 21:2032-2041.
27. Ono S, Kurotaki T, Nakasone T, et al. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand. Jpn J Infect Dis 2006, 59:168-173.